



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 35/16, 35/26, 37/04</b> <b>C12N 5/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/05793</b> <b>(43) International Publication Date:</b> 16 April 1992 (16.04.92)
<b>(21) International Application Number:</b> PCT/US91/07283 <b>(22) International Filing Date:</b> 4 October 1991 (04.10.91)  <b>(30) Priority data:</b> 593,083                      5 October 1990 (05.10.90)                      US  <b>(71) Applicant (for all designated States except US):</b> MEDAREX, INC. [US/US]; 22 Commerce Drive, West Lebanon, NH 03784 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ROMET-LEMONNE, Jean-Loup [FR/FR]; 46, rue Vatonne, F-91190 Gif-Yvette (FR). FANGER, Michael, W. [US/US]; West View Lane, Box 421, Lebanon, NH 03766 (US).		<b>(74) Agents:</b> DECONTI, Giulio, A., Jr. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TARGETED IMMUNOSTIMULATION WITH BISPECIFIC REAGENTS  <b>(57) Abstract</b> <p>Immune response against an antigen is stimulated by administering the antigen in conjunction with a binding agent specific for an antigen-presenting cell such as a macrophage. The binding agent specifically binds a receptor of the antigen-presenting cell, such as an FC receptor, without being blocked by the endogenous ligand for the receptor.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

-1-

TARGETED IMMUNOSTIMULATION  
WITH BISPECIFIC REAGENTS

Background

Antigen molecules are recognized by the immune  
05 system after internal processing by antigen-presenting  
cells, generally mononuclear phagocytic cells such as  
macrophages. In order to present a proteinaceous  
antigen, the antigen-presenting cell first  
internalizes the antigen which is then broken down  
10 into small peptidic fragments by enzymes contained in  
vesicles in the cytoplasm of the antigen-presenting  
cells. After fragmentation, the peptides are linked  
to cellular major histocompatibility complex (MHC)  
molecules and presented on the presenting cell's  
15 surface to the immune system. Peptides presented in  
this way are recognized by the T-cell receptor which  
engages T-lymphocytes into the immune response against  
this antigen. This antigen presentation also  
stimulates the B lymphocytes for specific antibody  
20 production.

Complexes of antibody and antigen have been used  
to stimulate an immune response against the antigen.  
Antigen uptake through antigen-antibody conjugates  
bound to FcγR increases the efficiency of antigen  
25 presentation and thereby antigen-specific T-cell  
activation by human and mouse macrophages. Celis, E.  
and Chang, T.W. (1984) Science 224:297-299; Chang,

-2-

T.W. (1985) Immunol. Today 6:245-259; Manca, R. et al. (1988) Immunol. 140:2893-2898; Schalke, B.C.G. et al. (1985) J. Immunol. 134:3643; and Snider, D.P. and Segal, D.M. (1987) J. Immunol. 139:1053-1059. The  
05 binding of these complexes to Fc $\gamma$ R is mediated by the Fc region of the antibody. This binding is susceptible to inhibition by physiological level of IgG.

#### Summary of the Invention

10 This invention pertains to a method of stimulating the immune response to an antigen by administering the antigen in conjunction with a binding agent which binds a surface receptor of an antigen-presenting cell without being blocked by  
15 natural ligand for the receptor and targets the antigen to the antigen-presenting cell.

In one embodiment, a bispecific binding agent is employed to target the antigen. The bispecific binding reagent has a binding specificity for the  
20 antigen and a binding specificity for a surface receptor of an antigen-presenting cell, such as a mononuclear phagocyte (e.g., a macrophage). The bispecific binding agent binds the cellular receptor, such as an Fc receptor, and targets the antigen,  
25 without substantially being blocked by the natural ligand for the receptor. In a preferred embodiment, the bispecific binding agent specifically binds the Fc receptor of an antigen-presenting cell for immunoglobulin G (IgG) without being blocked by IgG.  
30 In a particularly preferred embodiment, the agent specifically binds the high affinity Fc receptor for immunoglobulin G (Fc $\gamma$ RI).

-3-

The bispecific binding agent can be a bispecific antibody or heteroantibody. The antigen to be targeted can be derived from a foreign pathogen or it can be derived from endogenous diseased host cells  
05 such as tumor cells. Generally, the antigen is administered as a preformed complex with the bispecific reagent. In some cases, however, the antigen and the bispecific binding agent may be administered separately or the bispecific binding  
10 agent may be administered alone.

In another embodiment of the invention, the antigen is directly bound to a receptor-binding agent to create bispecific molecules. For example, the antigen can be covalently coupled to an antibody  
15 which binds the Fc receptor without being blocked by IgG.

The method and compositions of this invention can be used to treat or prevent infectious diseases, to neutralize the acute phase of an infection by a  
20 pathogenic organism, to stimulate the immune system in instances of chronic infection of such an organism and to treat tumors.

#### Brief Description of the Figure

Figure 1 illustrates the enhanced antigen  
25 presentation by directing antigen to human FcγR.

#### Detailed Description of the Invention

In the method of this invention, an antigen is targeted to an antigen-presenting cell to enhance the processes of internalization and presentation by  
30 these cells. In one embodiment of the invention, a bispecific binding reagent is employed to target the

-4-

antigen to the cell. The bispecific binding agent specifically binds the antigen (either directly, to an epitope of the antigen or indirectly, to an epitope attached to the antigen) and, at the same  
05 time, binds a surface receptor of an antigen-presenting cell which can internalize antigen for processing and presentation. The receptor-binding component of the bispecific binding agent (and thus the bispecific binding agent itself) binds the  
10 receptor of the antigen-presenting cell without substantially being blocked by the natural ligand for the receptor. As a result, targeting of the antigen to the receptor will not be prevented by physiological levels of the ligand and the targeted  
15 receptor will remain capable of binding the ligand and functioning.

The preferred surface receptors of antigen-presenting cells for targeting are the receptors for the Fc region of IgG (FcγR). These receptors can  
20 mediate internalization of antibody-complexed antigens. The most preferred target is the high affinity Fc receptor (FcγRI). As described in more detail below, the bispecific binding agents are generally made of antibodies, antibody fragments or  
25 analogues of antibodies containing antibody-derived, antigen-binding (variable) regions. Antibodies that bind to Fc receptors on antigen-presenting cells, and whose binding to the receptor is not blocked by the natural ligand, can be produced by conventional  
30 monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein (1975) Nature 256:495. Although somatic cell hybridization procedures are preferred, in

-5-

principle, other techniques for producing monoclonal antibodies can be employed e.g., viral or oncogenic transformation of B lymphocytes.

In general, an animal is immunized with an  
05 Fc $\gamma$ R-bearing cell, a receptor-bearing portion thereof  
or the Fc receptor molecule in purified or partially  
purified form. Antibodies are selected which bind an  
epitope of the Fc $\gamma$ R which is located outside of the  
ligand (i.e., Fc) binding domain of the receptor.  
10 This binding is not inhibited by IgG and, in turn,  
does not inhibit the binding of IgG and the function  
of the Fc receptor.

The production and characterization of mono-  
clonal antibodies which bind Fc $\gamma$ RI without being  
15 blocked by human IgG are described by Fanger et al.  
in PCT application WO 88/00052 and in U.S. Patent No.  
4,954,617, the teachings of which are incorporated by  
reference herein. These antibodies bind to an  
epitope of Fc $\gamma$ RI which is distinct from the Fc  
20 binding site of the receptor and, thus, their binding  
is not blocked substantially by physiological levels  
of IgG. Specific anti-Fc $\gamma$ RI antibodies useful in  
this invention are mab 22, mab 32, mab 44, mab 62 and  
mab 197. The hybridoma producing mab 32 is available  
25 from the American Type Culture Collection, Rockville,  
MD, ATCC No. HB9469.

The bispecific binding agent for targeting the  
antigen can be a heteroantibody, a bispecific  
antibody or an analogue of either of these.  
30 Bispecific antibodies are single, divalent antibodies  
which have two different antigen binding sites  
(variable regions). In the bispecific antibodies of  
this invention, one of the antigen binding sites is

specific for the receptor of the antigen-presenting cell and has the characteristics set forth above, and the other binding site is specific for the antigen to be targeted to the antigen-presenting cell. These  
05 antibodies can be produced by chemical techniques (see e.g., Kranz, D.M. et al. (1981) Proc. Natl. Acad. Sci. USA 78:5807), by "polydoma" techniques (See U.S. Patent 4,474,893, to Reading) or by recombinant DNA techniques.

10 Heteroantibodies are two or more antibodies or antibody-binding fragments (Fv, Fab, Fab' or F(ab')<sub>2</sub>) of different binding specificity linked together. Heteroantibodies comprise an antibody (or antigen-binding fragment) specific for the receptor of the  
15 antigen-presenting cell, coupled to an antibody (or antigen binding fragment) specific for the antigen to be targeted. Heteroantibodies can be prepared by conjugating together two or more antibodies or antibody fragments. Preferred heteroantibodies are  
20 comprised of crosslinked Fab fragments. A variety of coupling or crosslinking agents can be used to conjugate the antibodies. Examples are protein A, carboiimide, N-succinimidyl-S-acetyl-thioacetate (SATA) and N-succinimidyl-3-(2-pyridyldithio)  
25 propionate (SPDP). See e.g., Karpovsky et al. (1984) J. Exp. Med. 160:1686; Liu, M.A. et al. (1985) Proc. Natl. Acad. Sci. USA 82:8648. Other methods include those described by Paulus, H. Behring Inst. Mitt., No. 78, 118-132 (1985); Brennan et al. (1985) Science  
30 229:81-83 or Glennie et al. (1987) J. Immunol. 139:2367-2375.



-7-

Bispecific binding agents can also be prepared from single chain antibodies. See e.g., Huston, J.S. et al. (1988) Proc. Natl. Acad. Sci. 85:5879; Skerra, A. and Pluczhun, A. (1988) Science 240:1038. These  
05 are analogues of antibody variable regions produced as a single polypeptide chain. To form the bispecific binding agent, the single chain antibodies may be coupled together chemically or by genetic engineering methods.

10 As used herein, the term antigen means any natural or synthetic antigenic substance, a fragment or portion of an antigenic substance, a peptidic epitope, or a hapten. Suitable antibodies against wide variety of antigens for construction of the  
15 bispecific binding agents are available or can be readily made by standard techniques.

In some cases, it may be desirable to couple a substance which is weakly antigenic or nonantigenic in its own right (such as a hapten) to a carrier  
20 molecule, such as a large immunogenic protein (e.g., a bacterial toxin) for administration. In these instances, the bispecific binding reagent can be made to bind an epitope of the carrier to which the substance is coupled, rather than an epitope of the  
25 substance itself.

In another embodiment of the invention, the antigen can be coupled directly to the binding agent for the receptor. For example, an antigen can be coupled to an antibody, or fragment thereof, specific  
30 for an Fc receptor of an antigen-presenting cell. Proteinaceous antigens can be coupled by the methods described above or by other methods.

-8-

The antigen targeted by the method of this invention can be soluble or particulate; it may carry B cell epitopes, T cell epitopes or both. The antigen can be bacterial, viral or parasitic in origin. Often, the antigen will comprise a component of the surface structure of a pathogenic organism. For example, the antigen can comprise a viral surface structure such as an envelope glycoprotein of human immunodeficiency virus (HIV) or the surface antigen of hepatitis virus. In addition, the antigen can be associated with a diseased cell, such as a tumor cell, against which an immune response may be raised for treatment of the disease. The antigen can comprise a tumor-specific or tumor-associated antigen, such as the Her-2/neu proto-oncogene product which is expressed on human breast and ovarian cancer cells (Slamon, D.J. *et al.* (1989) *Science* 244:707).

Targeted immunostimulation can be performed in vitro or in vivo. The bispecific binding agent can be used to target an antigen to antigen-presenting cells in culture. Immunocompetent cells are separated and purified from patient blood. The cells are exposed to the antigen and the binding agent. Targeted antigen-presenting cells will process the antigen and present fragments on their surface. After stimulation, the cells can be returned to the patient.

To elicit an immune response in vivo, the antigen can be administered to a host in conjunction with the binding agent. Although in some circumstances the two may be administered separately, typically, they are administered as a preformed immunochemical complex. The complex is formed by

incubating the antigen and the bispecific binding agent at a desired molar ratio under conditions which permit binding of the two species. For example, the antigen and the bispecific binding reagent can be  
05 incubated in saline solution at 37°C. In some embodiments, for therapy of a pre-existing condition, the bispecific binding agent may be given without accompanying antigen.

The complex is administered in a physiologically  
10 acceptable solution at a dosage which will evoke an immune response against the antigen. The optimum dose of antigen, as well as the molar ratio of antigen and binding agent, may vary dependent upon factors such as the type of antigen, the immune  
15 status of the host, the type of infection or other disease being treated, etc. In most cases, the dose of antigen required to elicit an immune response (as determined by any standard method for assessment of immune response) should be lower than that which  
20 would be required if the antigen were given alone or as a complex with a monospecific antibody for the antigen.

The method of this invention can be used to enhance or reinforce the immune response to an  
25 antigen. For example, the method is valuable for the treatment of chronic infections, such as hepatitis and AIDS, where the unaided immune system is unable to overcome the infection. It can also be used in the treatment of the acute stages of infection when  
30 reinforcement of immune response against the invading organism may be necessary.

-10-

The method can be used to reduce the dose of antigen required to obtain a protective or therapeutic immune response or in instances when the host does not respond or responds minimally to the antigen. Although generally desirable, the lowering of effective dose can be especially desirable when the antigen is toxic to the host.

The method of targeted immunostimulation can also be used in disease therapy. For example, the bispecific binding agent can be used to target a tumor-associated (or tumor-specific) antigen to an antigen-presenting cell in order to cause or to enhance an immune response against the tumor.

The invention is illustrated further by the following exemplification:

#### Exemplification

##### Example 1

A bispecific heteroantibody was prepared from a monoclonal antibody against human erythrocytes (mono-D, a human anti-RhD antibody) and anti-Fc $\gamma$ RI antibody 32, by a protocol previously described. Shen, C. et al. (1986) J. Immunol. 137:3378. Human erythrocytes were washed three times in buffer solution and then incubated for 60 minutes at 37°C in solution of the heteroantibody. After the incubation and three washings, erythrocytes coated with heteroantibody were diluted at  $5 \times 10^7$  cells per millimeter in Hank's buffer and then incubated with adherent monocytes (macrophages) at the ratio of 100:1 for one hour at 37°C. Cells were then washed in phosphate buffered saline (PBS), fixed for one

-11-

minute in ethanol and stained with Giemsa for observation through a light microscope.

Internalization of erythrocytes was easily observed as unstained spheres in the macrophage cytoplasm. The number of macrophages that internalized at least one erythrocyte were counted. This experiment was repeated numerous times with and without the heteroantibody present. In each experiment, no erythrocyte internalization was observed in macrophages which were incubated with erythrocytes in the absence of the heteroantibody.

In addition, experiments were performed after treatment of adherent monocytes (macrophages) with various concentrations of interferon-gamma which is known to increase the number of FcγRI receptors on the macrophage surface. Petroni, K.C. *et al.* (1988) *J. Immunol.* 140:3467. As shown in the table below, the number of macrophages that internalized erythrocytes increased in a direct relation to the concentration of interferon-gamma.

Table

<u>Gamma Interferon</u>		<u>Percentage of Macrophages</u>
<u>Concentration (μg/ml)</u>		<u>Having Internalized at Least</u>
		<u>One Erythrocyte (%)</u>
25	1000	40
	100	25
	10	6

These data show that the heteroantibody can trigger internalization of antigen by macrophages.

-12-

Example 2 Enhanced Tetanus Toxoid (TT) presentation by directing TT to human FcγR.

Monoclonal antibody 22 (mAb 22) is specific for the high affinity Fcγ receptor and its binding to the  
05 receptor is not blocked by IgG Fc. See U.S. Patent No. 4,954,617. TT was conjugated to F(ab')<sub>2</sub> of mAb 22. To test the potential role of human antibody (Ab) isotype, TT was conjugated to non-specific H1gG<sup>1</sup>. TT (obtained from Accurate Chemical Co.,  
10 Westburg, NY) was linked to antibody or antibody fragments by the SATA-maleimide procedure.

The experiments were done in serum free AIM V medium (Gibco, Grand Island, NY) to minimize the contribution of undefined components such as  
15 hormones, lymphokines or monomeric and polymeric immunoglobulins. The use of AIM V reduces non-specific T cell responses while maintaining Ag-specific responses equal to those observed with other media tested. This medium allows more  
20 definitive studies of Fc receptor-enhanced antigen presentation in vitro. If antigen is directed to Fc receptors using mAb that bind to Fc receptors regardless of the presence of human IgG, this medium is not a requirement to see enhanced Ag presentation.

25 T cells used in the assay were primed with TT. When T cells are taken fresh from an individual there are T cells present which can potentially respond to many things (serum components, mouse Ig, etc.). By priming the cells in vitro (i.e., adding TT to fresh  
30 monocytes and T cells), only the T cells which recognize TT grow out. Thus, the cells are specific for TT.

-13-

The T cells were taken from the same donor as the monocytes. The vast majority (>85%) are CD4+, helper T cells specific for TT. They are polyclonal which means they likely recognize many parts of TT (i.e., many different 10-20 amino acid segments of TT as foreign). This is the type of response (polyclonal) which one might expect in vivo.

5 x 10<sup>4</sup> monocytes purified by cold aggregation and 5 x 10<sup>4</sup> T cells (primed once with TT, as described) were added in AIM V medium to wells of a 96 well plate. Subsequently, Ab, TT, TT-Ab, or anti-TT Ab + TT was added. Plates were incubated 72 hrs at 37°C at which time [<sup>3</sup>H]thymidine was added overnight. Cells were then harvested and counted.

Figure 1 shows the results of these experiments. Data is expressed as counts/minute (CPM) ± SD. As can be seen, TT conjugated to mAb 22 resulted in enhanced T cell proliferation over that obtained with TT alone, HIgG1-TT or anti-TT:TT complex. Ab alone did not induce T cell proliferation.

#### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

-14-

Claims

1. A method of stimulating an immune response to an antigen, comprising administering the antigen and a binding agent which binds a surface  
05 receptor of an antigen-presenting cell without being blocked substantially by the natural ligand for the receptor, so that the antigen is targeted to the receptor.
2. A method of claim 1, wherein the antigen is  
10 coupled to the binding agent.
3. A method of claim 2, wherein the binding agent is an antibody, or fragment thereof.
4. A method of claim 1, wherein the binding agent is bispecific, having a binding affinity for the  
15 receptor and for the antigens.
5. A method of claim 4, wherein the antigen and the bispecific binding agent are administered as a complex.
6. A method of claim 4, wherein the bispecific  
20 binding agent is a heteroantibody.
7. A method of claim 1, wherein the antigen is selected from the group consisting of viral, bacterial, parasite and tumor-associated antigen.
8. A method of claim 1, wherein the antigen is  
25 derived from hepatitis virus.



-15-

9. A method of claim 1, wherein the hepatitis antigen is hepatitis surface antigen.
10. A method of claim 1, wherein the antigen is an HIV antigen.
- 05 11. A method of claim 1, wherein the antigen-presenting cell is a macrophage.
12. A method of claim 1, wherein the surface receptor of the macrophage is a receptor for immunoglobulin Fc.
- 10 13. A method of claim 12, wherein the receptor for immunoglobulin Fc is the high affinity Fc receptor for immunoglobulin G.
14. A method of stimulating an immune response against an antigen, comprising administering a  
15 molecular complex comprising an antigen and a bispecific heteroantibody, the heteroantibody comprising a first antibody, or fragment thereof, which specifically binds the Fc receptor for immunoglobulin G (IgG) on the  
20 macrophage surface without being blocked substantially by IgG and a second antibody, or fragment thereof, which specifically binds the antigen.
15. A method of claim 14, wherein the bispecific  
25 antibody comprises a Fab x Fab conjugate.

-16-

16. A method of treating hepatitis B infection comprising administering to an individual infected with the virus a molecular complex comprising hepatitis B surface antigen, or  
05 portion thereof, and a Fab x Fab heteroantibody wherein the first Fab binds the high affinity Fc receptor for immunoglobulin G without being blocked substantially by IgG and the second Fab binds the antigen.
- 10 17. A method of stimulating an immune response to an antigen, comprising administering a complex of the antigen coupled to a binding agent which binds an antigen-presenting cell without being  
15 blocked substantially by the natural ligand for the receptor.
18. A method of claim 17, wherein the surface receptor of the macrophage is a receptor for immunoglobulin Fc.
19. A molecular complex comprising an antigen  
20 complexed to a bispecific binding agent which binds a surface receptor of an antigen-presenting cell without being blocked substantially by the natural ligand for the receptor and binds the antigen.
- 25 20. A molecular complex of claim 19, wherein the bispecific binding agent is a heteroantibody.

-17-

21. A molecular complex of claim 20, wherein the heteroantibody comprises chemically crosslinked Fab or Fab' antibody fragments.
- 05 22. A molecular complex of claim 19, wherein the antigen is selected from the group consisting of viral, bacterial, parasite and tumor-associated antigen.
23. A molecular complex of claim 19, wherein the antigen is a hepatitis antigen.
- 10 24. A molecular complex of claim 19, wherein the antigen is an HIV antigen.
25. A molecular complex of claim 19, wherein the antigen-presenting cell is a macrophage.
- 15 26. A molecular complex of claim 25, wherein the surface component of the macrophage is a receptor for immunoglobulin Fc.
27. A molecular complex of claim 26, wherein the receptor for immunoglobulin Fc is the high affinity Fc receptor for immunoglobulin G.
- 20 28. A molecular complex, comprising an antigen and a bispecific heteroantibody, the heteroantibody comprising a first antibody, or fragment thereof, which specifically binds an Fc receptor for immunoglobulin G (IgG) on the macrophage  
25 surface without being blocked substantially by IgG and a second antibody, or fragment thereof, which specifically binds the antigen.

-18-

29. A molecular complex of claim 28, wherein the first antibody, or fragment thereof, binds the high affinity Fc receptor for IgG.
- 05 30. A molecular complex of claim 28, wherein the antigen is selected from the group consisting of a viral, bacterial, parasitic and disease-associated antigen.
31. A molecular complex of claim 28, wherein the antigen is a hepatitis antigen.
- 10 32. A molecular complex of claim 25, wherein the hepatitis antigen is hepatitis surface antigen.
33. A molecular complex of claim 26, wherein the antigen is an HIV antigen.
- 15 34. A molecular complex, comprising an antigen and a Fab x Fab heteroantibody, wherein the first Fab binds the high affinity Fc receptor for immunoglobulin G (IgG) without being blocked by IgG and the second Fab binds the antigen.
- 20 35. A vaccine composition, comprising a molecular complex of claim 19 in a pharmaceutically acceptable vehicle.
- 25 36. An antigen linked to an antibody, a fragment or analogue thereof, which binds the Fc $\gamma$  receptor of an antigen-presenting cell without being blocked by IgG Fc.

1/1




FIG. 1

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/07283

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): A61K 35/16, 35/26, 37/04; C12N 5/02 USCL.: 424/85.8, 88; 530/387		
<b>II. FIELDS SEARCHED</b> Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
USCL.	424/85.8, 88; 530/387	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X Y	US.A. 4,950,480 (Barber et al.) 21 August 1990. see abstract. summary of invention. Examples I-III.	1-7.11-20 21-36
X Y	WO.A. 88/00052 (Fanger et al.) 14 January see entire document.	1-36 1-36
<p><sup>*</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
20 January 1992		10 FEB 1992
International Searching Authority		Signature of Authorized Officer
ISA/USA		Lila Feisee